Alex Biese

The investigational drug LSTA1 is being explored for the treatment of osteosarcoma, which starts in the bones and accounts for 2% of childhood cancers.

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the needs of caregivers for adolescent and young adult patients with cancer.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the issues faced by adolescent and young adult patients with cancer as they age into adult care.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about how a cancer diagnosis ‘adds a new identity’ for adolescent and young adult patients.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the power of mindfulness practices such as yoga and meditation.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the current landscape of research for adolescent and young adult patients with cancer.

One expert explains how caregivers are a vital part of the care team during a clinical trial.

Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.

The Food and Drug Administration granted an accelerated approval to Iclusig, described as the new “standard of care” for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

During the Miami Breast Cancer Conference and Educated Patient® Breast Cancer Summit, one expert stressed the importance of genetic testing for BRCA mutations.

The director of programs for the Dear Jack Foundation explains issues young patients with cancer may face into adulthood.

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.

With cybersecurity a pressing concern for patients, CURE® spoke with experts about protective measures they can take to protect themselves online.

A patient with breast cancer shares skills she’s learned from the Look Good Feel Better program at the Miami Breast Cancer Conference and Educated Patient® Breast Cancer Summit.

As part of its Speaking Out video series, CURE® spoke with Lisa Carter-Bawa of Hackensack Meridian Health about the role nurses play in helping patients manage treatment side effects.

As part of its Speaking Out video series, CURE® spoke with Upal Basu Roy of LUNGevity about recently approved treatments for lung cancer and what is on the horizon.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.

As part of its Speaking Out video series, CURE® spoke with Brandon Leonard of the LUNGevity Foundation about the role legislation can play in a patient’s cancer journey.

With cyberattacks on medical institutions on the rise, CURE® spoke with an online security expert about steps patients should take if they believe their data has been exposed.

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

Patients with small cell lung cancer have reasons to be optimistic these days, as one expert explains to CURE.

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options?

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.